Outcome of T-Lymphoblastic Leukemia-Lymphoma with Hyper C-VAD Regimen

Nasrin  Namdari; Elahe  Ataei; Fatame  Ghanbarian; Sezaneh  Haghpanah; Maral  Mokhtari

doi:10.18502/ijhoscr.v19i4.19981

Nasrin Namdari Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
Elahe Ataei Medical Student, University of Medical Sciences, Shiraz, Iran
Fatame Ghanbarian Medical Student, University of Medical Sciences, Shiraz, Iran
Sezaneh Haghpanah Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Maral Mokhtari Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran

DOI: https://doi.org/10.18502/ijhoscr.v19i4.19981

Keywords: T-ALL; T-LBL; Hyper-CVAD chemotherapy; Allogeneic SCT; Progression-Free Survival

Abstract

Background: T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are aggressive diseases with dismal prognoses.

Materials and Methods: All adult patients with T-ALL and T-LBL who were candidates for the Hyper-CVAD chemotherapy protocol were included. We evaluated overall survival and progression-free survival in 46 new cases. The T-ALL and T-LBL’s number of cases were 32 and 14, respectively.

Results: Two- and 3-year OS were 41.8% (standard error (SE): 7%) and 27.8% (SE: 7%), respectively. Two- and 3-year PFS were 36.9% (SE: 7%) and 25.3% (SE: 7%), respectively. The only variable that had a significant relationship with the duration of PFS and OS was Allogenic SCT. Patients receiving Allogeneic SCT had longer survival time (2-year overall survival of 80% against 20%) (p˂0.001).

Conclusion: These data support the concept that Hyper-CVAD is not an appropriate and adequate regimen. We need new targeted agents in the T-ALL and T-LBL induction regimen while considering Allogeneic SCT as a Consolidation.